Relationship between sleep apnea, fat distribution, and insulin resistance in obese children

Craig A Canapari1, Alison G Hoppin, T Bernard Kinane

  • 1Division of Pediatric Pulmonology, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA. ccanapari@partners.org

Insights

Visceral fat, not just overall obesity, is a key predictor of obstructive sleep apnea (OSA) severity in children. This finding highlights the importance of fat distribution in pediatric OSA.

Area of Science:

  • Pediatric Endocrinology
  • Sleep Medicine
  • Obesity Research

Background:

  • Obstructive sleep apnea (OSA) is linked to obesity, inflammation, and insulin resistance in children.
  • The specific role of fat distribution in the development of pediatric OSA remains unclear.
  • Understanding these relationships is crucial for managing obese children's health.

Purpose of the Study:

  • To investigate the connection between fat distribution, OSA, and insulin resistance in obese children.
  • To determine if fat distribution patterns are independent predictors of OSA in this population.

Main Methods:

  • Study included obese children (age 5-18 years) with BMI > 95th percentile.
  • Participants underwent polysomnography, blood tests for dyslipidemia, inflammation, and insulin resistance (HOMA).
  • A subset received MRI/MRS to quantify visceral and subcutaneous adipose tissue and intramyocellular lipids.

Main Results:

  • 48% of the 31 enrolled obese children had OSA (mean AHI 6.26 events/h).
  • Children with OSA showed higher BMI, triglycerides, leptin, and HOMA scores.
  • Visceral fat area significantly predicted OSA severity (AHI), independent of BMI z-score, age, or gender.

Conclusions:

  • Visceral fat distribution is a significant and independent predictor of obstructive sleep apnea severity in obese children.
  • Targeting visceral adiposity may be a key strategy in managing pediatric OSA.
Abstract

Related Concept Videos

Sleep Apnea01:21

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Insufficient Sleep and Sleep Deprivation01:13

Insufficient Sleep and Sleep Deprivation

Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...